Gene Splicing Switch Drives Blood Vessel Aging and Atherosclerosis
Scientists discover how a molecular switch in blood vessel cells accelerates aging and plaque formation, revealing new therapeutic targets.
Summary
Researchers discovered that a molecular switch in the FGFR2 gene drives blood vessel aging and atherosclerosis development. When cells are stressed, they produce a different version of this protein that creates a harmful feedback loop, causing endothelial cells lining blood vessels to age faster and secrete inflammatory substances. This process accelerates plaque formation in arteries. The study used human samples, animal models, and genetically modified mice to demonstrate that blocking this specific protein variant reduced arterial plaque formation and cellular aging. The findings identify FGFR2-IIIc as a potential therapeutic target for preventing age-related cardiovascular disease.
Detailed Summary
This groundbreaking research reveals how a molecular switch in blood vessel cells accelerates cardiovascular aging and atherosclerosis. The discovery could lead to new treatments for preventing age-related heart disease.
Scientists investigated how alternative splicing of the FGFR2 gene affects endothelial cells that line blood vessels. These cells normally produce two protein variants, but aging and stress shift production toward the FGFR2-IIIc variant, which proves harmful.
Researchers used human tissue samples, animal models, and genetically engineered mice to track this process. They found that the FGFR2-IIIc variant creates a destructive feedback loop with FGF2 protein, activating cellular pathways that drive senescence. Senescent cells stop dividing and release inflammatory substances that damage surrounding tissue.
The key mechanism involves a splicing factor called hnRNP H1, which responds to cellular stress by promoting production of the harmful FGFR2-IIIc variant. This creates an autocrine loop that pushes endothelial cells into a senescent state, accelerating atherosclerotic plaque formation.
When researchers knocked out FGFR2-IIIc specifically in endothelial cells of atherosclerosis-prone mice, they observed significantly reduced plaque formation, decreased inflammatory gene expression, and less cellular senescence compared to controls.
These findings suggest that targeting FGFR2-IIIc or the splicing machinery that produces it could prevent cardiovascular aging. However, the research was conducted primarily in mice, and human trials would be needed to confirm therapeutic potential. The complexity of splicing regulation also presents challenges for drug development.
Key Findings
- FGFR2-IIIc protein variant increases in aging blood vessels and drives cellular senescence
- Blocking FGFR2-IIIc in mice reduced arterial plaque formation and vascular aging
- Stress-induced splicing creates harmful FGF2-FGFR2-IIIc feedback loop in endothelial cells
- hnRNP H1 splicing factor mediates the switch to pro-aging FGFR2 variant
Methodology
Study used human clinical samples, animal aging models, and genetically engineered ApoE-/- mice with endothelial-specific FGFR2-IIIc manipulation. Combined in vivo and in vitro approaches to investigate splicing mechanisms and senescence pathways.
Study Limitations
Research conducted primarily in mouse models may not fully translate to humans. Complex splicing regulation presents challenges for therapeutic targeting. Long-term safety of modulating FGFR2 splicing requires further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.